Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Calgary

$27,000.00

Mechanisms of B-Glucan-Mediated Modulation of Trained Immunity in Inflammatory Bowel Disease

EF 2025-26

Résumé
Inflammatory bowel disease (IBD) describes a variety of conditions (e.g., Crohn’s disease and ulcerative colitis) characterized by chronic inflammation of the gut. The worldwide and national prevalence of IBD is rapidly on the rise, and it has been projected that 1 in every 90 individuals in Canada will be diagnosed in 2035. Current treatment approaches for IBD include pharmacological therapy, surgery, and fecal microbiota transplantation. The current interventions have significant limitations, such as unwanted side effects and a lack of efficacy in some patients. Due to the increasing IBD prevalence and the major limitations of the current interventions, there is an urgency to develop novel IBD treatments. B-Glucan, a microbial and plant-derived polysaccharide, has been demonstrated to maintain gut epithelial integrity and foster beneficial microbes in the microbiota. We propose that B-Glucan may serve as an effective IBD therapy by altering the gut microbiota, which in turn interacts and functionally reprograms the hematopoietic stem cells (HSCs) in the bone marrow. Subsequently, the HSCs differentiate into anti-inflammatory macrophages to alleviate IBD symptoms and improve disease outcomes. To test this hypothesis, we will treat mice with B-Glucan, and their fecal matter will be analyzed to investigate changes in the microbiota composition. Furthermore, mice bone marrow and colon will be examined via flow cytometry to identify any differing immune cell populations. This research provides insight into how B-Glucan can influence the interaction between the microbiota and the immune system in the context of IBD. These findings may guide the development of B-Glucan-based therapies for IBD patients in the future.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
572855
Name
Cheung Derek
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanisms of B-Glucan-Mediated Modulation of Trained Immunity in Inflammatory Bowel Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
B-Glucan; Epigenetic; Hematopoietic Stem Cells; Inflammation; Inflammatory Bowel Disease; Innate Immunity; Maladaptive Trained Immunity; Microbiome; Trained Immunity; Ulcerative Colitis
Abstract
Inflammatory bowel disease (IBD) describes a variety of conditions (e.g., Crohn’s disease and ulcerative colitis) characterized by chronic inflammation of the gut. The worldwide and national prevalence of IBD is rapidly on the rise, and it has been projected that 1 in every 90 individuals in Canada will be diagnosed in 2035. Current treatment approaches for IBD include pharmacological therapy, surgery, and fecal microbiota transplantation. The current interventions have significant limitations, such as unwanted side effects and a lack of efficacy in some patients. Due to the increasing IBD prevalence and the major limitations of the current interventions, there is an urgency to develop novel IBD treatments. B-Glucan, a microbial and plant-derived polysaccharide, has been demonstrated to maintain gut epithelial integrity and foster beneficial microbes in the microbiota. We propose that B-Glucan may serve as an effective IBD therapy by altering the gut microbiota, which in turn interacts and functionally reprograms the hematopoietic stem cells (HSCs) in the bone marrow. Subsequently, the HSCs differentiate into anti-inflammatory macrophages to alleviate IBD symptoms and improve disease outcomes. To test this hypothesis, we will treat mice with B-Glucan, and their fecal matter will be analyzed to investigate changes in the microbiota composition. Furthermore, mice bone marrow and colon will be examined via flow cytometry to identify any differing immune cell populations. This research provides insight into how B-Glucan can influence the interaction between the microbiota and the immune system in the context of IBD. These findings may guide the development of B-Glucan-based therapies for IBD patients in the future.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheung, Derek
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~